Black Diamond Therapeutics, Inc.
BDTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001701541
No open-market purchases or sales by Black Diamond Therapeutics, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $64.9M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $92.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −7 vs. previous quarter
- 96
- 13F valueReported value at the end of Q2 2026
- $64.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $70.0M
- No comparable prior period
- Net income, FY2025
- $22.4M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.11M
- Shares sold short
- Change
- +103.4K
- +2.1% vs. previous
- Days to cover
- 4.87
- At average daily volume
Superinvestors holding BDTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding BDTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Black Diamond Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 20, 2025 (view filing)9:01 PM ET | Mar 19 | 1 day | BB Biotech AG and 1 other10% Owner | SSale | −5.78M | $2.07 | −$12.0M | −67.9%2.73M after | 7 lots |
| Aug 30, 2024 (view filing)4:16 PM ET | Aug 28 | 2 days | Versant Venture Capital VI, L.P. and 3 others10% Owner | SSale | −221.6K | $6.32 | −$1.40M | −5.6%3.73M after | |
| Oct 19, 2023 (view filing)3:08 PM ET | Oct 17 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +400.0K | $2.34 | +$934.1K | +4.9%8.52M after | |
| Jul 7, 2023 (view filing)4:30 PM ET | Jul 5 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector | PPurchase | +935.9K | $5.00 | +$4.68M | +41.1%3.21M after | |
| Jul 6, 2023 (view filing) | Jul 5 | 1 day | Behbahani AliDirector | PPurchase | +1.00M | $5.00 | +$5.00M | +29.0%4.45M after | |
| Jul 3, 2023 (view filing)3:36 PM ET | Jun 30 | 3 days | BB Biotech AG and 1 other10% Owner | PPurchase | +1.00M | $5.00 | +$5.00M | +14.0%8.12M after | |
| Jun 29, 2023 (view filing)1:37 PM ET | Jun 27 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +1.74M | $5.49 | +$9.56M | +32.4%7.12M after | |
| Jun 28, 2023 (view filing) | Jun 27 | 1 day | Epstein David M.SEE REMARKS | SSale | −25.0K | $6.70 | −$167.5K | −3.6%671.4K after | 10b5-1 |
| Dec 23, 2022 (view filing) | Dec 21-22 | 2 days | Ni FangSEE REMARKS | PPurchase | +56.4K | $1.28 | +$72.3K | +81.7%125.4K after | 2 lots |
| Nov 2, 2022 (view filing)3:10 PM ET | Oct 31 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +99.8K | $2.25 | +$224.9K | +1.9%5.38M after |
Top 10 13F holders, Q2 2026
See all 96 holdersThe largest institutional positions in Black Diamond Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 4,448,757 | $8.23M | 0.52% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 4,028,202 | $7.45M | 0.00% | −6,534,901−61.9% | Reduced |
| BlackRock, Inc. | 3,917,088 | $7.25M | 0.00% | +2,810,248+253.9% | Added |
| Acadian Asset Management LLC | 2,348,651 | $4.34M | 0.01% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,125,270 | $3.93M | 0.00% | +274,802+14.9% | Added |
| Renaissance Technologies LLC | 1,962,394 | $3.63M | 0.00% | +318,647+19.4% | Added |
| Defilade Capital Management, L.P. | 1,674,999 | $3.10M | 0.41% | +1,674,999 | New |
| Dimensional Fund Advisors LP | 1,365,384 | $2.53M | 0.00% | +63,720+4.9% | Added |
| Geode Capital Management, LLC | 1,218,171 | $2.25M | 0.00% | +681,596+127.0% | Added |
| Connor, Clark & Lunn Investment Management Ltd. | 1,092,885 | $2.02M | 0.00% | +34,488+3.3% | Added |
Holders of 5% or more of BDTX
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Black Diamond Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 7.00%4.03M shares | – | Feb 14, 20245 filings | Jul 8, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.70%3.84M shares | +2.20 ppfrom 4.50% | Oct 24, 20244 filings | Jul 27, 2026 | SEC |